whitepaper

Whitepaper: Application of CRISPR/Cas to the generation of genetically engineered mice

Posted: 7 January 2019 | | No comments yet

Learn how the continued development of CRISPR gene editing technologies opens fresh possibilities for in vivo model design.

CRISPR/Cas-based gene editing technologies continue to expand the capabilities of bioscience and drug discovery researchers. Existing processes have matured, while whole new applications — such as large, exogenous insertions — open exciting possibilities for efficiently modelling human disease.

Download this updated white paper to find out how CRISPR/Cas technologies can streamline and accelerate your genetic engineering projects, while costing significantly less than pre-CRISPR gene editing techniques.

The rest of this whitepaper is restricted - login or subscribe free to access

Drug Target Review issue 4 2018 coverThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 


Send this to a friend